ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1136

Transcriptional Heterogeneity of the SLC2A9 Gene Encoding the GLUT9 Urate Transporter

David B. Mount1,2, Tony R. Merriman3, Eli A. Stahl4, Hyon K. Choi5 and Asim Mandal1, 1Renal Division, Brigham and Women's Hospital, Boston, MA, 2Renal Division, VA Boston Healthcare System, Boston, MA, 3Department of Biochemistry, University of Otago, Dunedin, New Zealand, 4Mt Sinai School of Medicine, New York City, NY, 5Boston University School of Medicine, Boston, MA

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Gene Expression, genetics, genomics, gout and hyperuricemia

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Genetics, Genomics and Proteomics II

Session Type: Abstract Submissions (ACR)

Background/Purpose: Variation in SLC2A9, which encodes the urate transporter GLUT9, is the major single genetic determinant of serum uric acid (SUA); however, the causal variant(s) within SLC2A9 have not been identified.  Two distinct N-terminal isoforms, GLUT9a, (540 residues) and GLUT9b (511 residues), are generated by alternative 5′ ends.  Our aim was to characterize the 5′ end of SLC2A9to further understanding of how variation in this gene affects SUA.

Methods: 5′ untranslated region (UTR) exons, alternative splicing, and transcriptional start sites were identified by database mining, 5′-RACE PCR, and RT-PCR.  GLUT9 cDNA expression constructs were characterized by 14C-urate uptakes in Xenopusoocytes.  Promoter analysis utilized the dual luciferase system.

Results: Seven novel 5′ UTR exons were identified, with substantial alternative splicing; in GLUT9b only exon 2, containing the start codon, is spared from alternative splicing. Alternative splicing that deletes coding exons 3 +/- 4 was also identified, in both GLUT9a and GLUT9b transcripts.  Exon 3 is a cassette exon encoding most of transmembrane domain 1 (TM1) and part of the first, glycosylated extracellular loop.  Surprisingly, GLUT9b constructs with deletion of exon 3 were functional (GLUT9b-delta3), generating urate uptakes that were 10-fold higher than that of control Xenopusoocytes.   Western blotting indicated that GLUT9b-delta3 protein is not glycosylated, presumably due to altered topology of the first extracellular, glycosylated loop.

A single GLUT9a transcriptional start site was identified, flanking exon 1a.  Luciferase constructs for this promoter were highly active in multiple cell lines, with a minimal promoter construct of ~200 bp.  Four GLUT9b start sites were identified, including one ~35 kb 5′ of exon 1b flanking a novel 5′ UTR exon.  Only 2 out of 4 GLUT9b promoters were functional, with substantially lower activity than the GLUT9a promoter.

Using the publically available Atherosclersis Risk in Communities Study dataset a major urate-increasing haplotype (freq=0.50) was identified spanning the promoter elements, in addition to two related urate-lowering haplotypes (freq=0.21) with the remaining haplotypes not significantly associated with urate levels.

Conclusion: There is substantial transcriptional heterogeneity in SLC2A9, with seven new 5′ UTR exons and at least four transcriptional initiation sites.  Alternative splicing that removes exon 3 generates functional GLUT9 urate transporters, despite removal of TM1.  The single GLUT9a promoter is strongly active in luciferase assays, whereas only 2 out of 4 GLUT9b promoters are weakly active. Relating these effects to genetic control of urate will increase understanding of the molecular basis of renal uric acid secretion.


Disclosure:

D. B. Mount,
None;

T. R. Merriman,
None;

E. A. Stahl,
None;

H. K. Choi,
None;

A. Mandal,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/transcriptional-heterogeneity-of-the-slc2a9-gene-encoding-the-glut9-urate-transporter/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology